Checking if brain sugar transport in type 2 diabetes improves with tighter glucose control
Tests whether brain sugar changes in adults with type 2 diabetes improve with control.
Plain-language title generated from the registry record
Registry title: Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
Key facts
- Where
- New Haven, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT05776563, who can take part
Where in United States
- Yale New Haven Hospital (YNHH) Research Unit (HRU)New Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT05776563
- Record updated
- 9 October 2026
- Original description
The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control.Read full original descriptionShow less
Reversibility of Brain Glucose Transport and Metabolism in T2DM
The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control.
The main question[s] it aims to answer are:
* To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control. * Assess which factors, (duration of diabetes mellitus (DM) and glycemic control) contribute to changes in glucose transport
Participants will have:
* A screening visit * placement of a continuous glucose monitor (CGM) 2 weeks before the first magnetic resonance spectroscopy (MRS) at week 0 * Additional visits/phone calls for intensification of diabetes management and nutrition visits * Second magnetic resonance spectroscopy (MRS) at week 12
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, aged 18-60; medical history for Type 2 diabetes; HbA1c > 7.5%, BMI ≥18 kg/m2; Be willing to adhere to the intensification of their diabetes regimen.
Exclusion: current or recent steroid use in last 3 months; illicit drug use; untreated thyroid disease,; uncontrolled hypertension; known neurological disorders; untreated psychiatric disorders; malignancy; bleeding disorders; Creatinine > 1.5 mg/dL; Hgb < 10 mg/dL, hematocrit of 37 % for males participants and 33 % for female participants; ALT >3 x ULN; for women: pregnancy, actively seeking pregnancy, or breastfeeding; inability to enter MRI/MRS (as per standard MRI safety guidelines).